CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...